

D. Risk Factors

The information (including tabular data) set forth or referenced under the heading “Additional Information–Risk” on pages 246 to 257 of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company

The information (including tabular data) set forth under the headings “Additional Information–Shareholder Information–History and development of the Company” on page 259, “Strategic Report–Financial Review– Collaboration Revenue” on pages 82 to 83, “Strategic Report–Financial Review–Financial position –31 December 2019– Business combinations” on page 87, “–Investments, divestments and capital expenditure” on pages 89 to 90, “Corporate Governance–Corporate Governance Report–Compliance with the UK Corporate Governance Code–Board Leadership and Company Purpose” on pages 108 to 109 and “Additional Information–Important information for readers of this Annual Report– AstraZeneca websites” on page 272, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

The United States Securities and Exchange Commission (the “SEC”) maintains a website at www.sec.gov which contains in electronic form each of the reports and other information that we have filed electronically with the SEC.

B. Business Overview

The information (including graphs and tabular data) set forth under the headings “Strategic Report–AstraZeneca at a glance” on pages 2 to 3, “–Chairman’s Statement” on page 4, “–Chief Executive Officer’s Review” on pages 5 to 7, “–Strategy” on pages 17 to 19, “–Key Performance Indicators” on pages 20 to 23, “–Business Review” on pages 24 to 26, “–Therapy Area Review” on pages 54 to 73, “– Risk Overview–Managing risk”, “–Risk Overview– Emerging risks” on page 74, “–Risk management embedded in business processes” on pages 74 to 75, “–Brexit” on page 75, “Corporate Governance–Corporate Governance Report–Other Governance information–Global Compliance and Internal Audit Services (IA)” on page 112, “Additional Information–Development Pipeline as at 31 December 2019” on pages 238 to 242, “–Patent Expiries of Key Marketed Products” on pages 243 to 245, “–Sustainability: supplementary information” on page 266, “Financial Statements–Notes to the Group Financial Statements–Note 1–Revenue” on pages 180 to 181, “–Note 6 –Segment information” on pages 185 to 187, and “Additional Information–Important information for readers of this Annual Report–Statements of competitive position, growth rates and sales” on page 272, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

On February 25, 2020, AstraZeneca announced that it had divested its global rights to *Movantik* (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). *Movantik* is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

On March 2, 2020, AstraZeneca announced that it had completed a previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

Geographical Review

This section Item 4–“Information on the Company– Business Overview–Geographical Review” should be read in conjunction with Item 5–“Operating and Financial Review and Prospects–Operating Results” below.